Needham & Company LLC Reiterates “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $11.00 price objective on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 107.94% from the stock’s previous close.

A number of other analysts have also recently weighed in on TCRX. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research note on Tuesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock opened at $5.29 on Wednesday. TScan Therapeutics has a one year low of $3.73 and a one year high of $9.69. The company has a market capitalization of $280.21 million, a PE ratio of -5.04 and a beta of 0.79. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.77 and a current ratio of 7.77. The company has a 50-day simple moving average of $5.35 and a two-hundred day simple moving average of $6.60.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02. The firm had revenue of $0.54 million during the quarter, compared to analyst estimates of $1.55 million. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. Research analysts expect that TScan Therapeutics will post -1.17 EPS for the current fiscal year.

Insider Transactions at TScan Therapeutics

In other news, Director Barbara Klencke bought 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were purchased at an average price of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the transaction, the director now directly owns 40,000 shares in the company, valued at approximately $221,200. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. In other TScan Therapeutics news, Director Barbara Klencke bought 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was bought at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $221,200. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Zoran Zdraveski sold 164,686 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the sale, the insider now directly owns 4,716 shares in the company, valued at $27,258.48. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders bought a total of 15,000 shares of company stock worth $82,550 over the last three months. 2.76% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TCRX. Dimensional Fund Advisors LP acquired a new stake in shares of TScan Therapeutics during the 2nd quarter worth approximately $70,000. SG Americas Securities LLC acquired a new stake in TScan Therapeutics during the third quarter valued at $78,000. The Manufacturers Life Insurance Company purchased a new position in TScan Therapeutics in the second quarter valued at $90,000. Cornercap Investment Counsel Inc. purchased a new position in TScan Therapeutics in the second quarter valued at $134,000. Finally, Rhumbline Advisers acquired a new position in shares of TScan Therapeutics in the second quarter worth about $274,000. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.